8-K
filed June 26, 2023, 7:59 PM ET
CIK 0000891293
M&A
confidence high
sentiment neutral
materiality 1.00
CTI BIOPHARMA CORP: M&A transaction — Sobi completes acquisition of CTI BioPharma at $9.10/share; shares delisted from Nasdaq
CTI BIOPHARMA CORP
- Tender offer expired with 110,640,230 shares (83.8%) validly tendered; merger closed June 26, 2023.
- Shareholders received $9.10 per share in cash; preferred stock converted at $91,000 per share.
- CTI notified Nasdaq, requested trading suspension and Form 25 filing to delist and deregister shares.
- Board replaced: prior directors resigned; new directors are Guido Oelkers, Henrik Stenqvist, Torbjörn Hallberg.
- Credit agreement with Drug Royalty III LP repaid in full and terminated on June 26, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Reed V. Tuckson resigned as Director at CTI BIOPHARMA CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
As of the Effective Time, Adam R. Craig, Laurent Fischer, David Parkinson, Diane Parks, Matthew D. Perry, Michael A. Metzger and Reed V. Tuckson each ceased to be directors of CTI and members of any committee of CTI’s board of directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Adam R. Craig resigned as Director at CTI BIOPHARMA CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
As of the Effective Time, Adam R. Craig, Laurent Fischer, David Parkinson, Diane Parks, Matthew D. Perry, Michael A. Metzger and Reed V. Tuckson each ceased to be directors of CTI and members of any committee of CTI’s board of directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
David Parkinson resigned as Director at CTI BIOPHARMA CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
As of the Effective Time, Adam R. Craig, Laurent Fischer, David Parkinson, Diane Parks, Matthew D. Perry, Michael A. Metzger and Reed V. Tuckson each ceased to be directors of CTI and members of any committee of CTI’s board of directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Michael A. Metzger resigned as Director at CTI BIOPHARMA CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
As of the Effective Time, Adam R. Craig, Laurent Fischer, David Parkinson, Diane Parks, Matthew D. Perry, Michael A. Metzger and Reed V. Tuckson each ceased to be directors of CTI and members of any committee of CTI’s board of directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Laurent Fischer resigned as Director at CTI BIOPHARMA CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
As of the Effective Time, Adam R. Craig, Laurent Fischer, David Parkinson, Diane Parks, Matthew D. Perry, Michael A. Metzger and Reed V. Tuckson each ceased to be directors of CTI and members of any committee of CTI’s board of directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Diane Parks resigned as Director at CTI BIOPHARMA CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
As of the Effective Time, Adam R. Craig, Laurent Fischer, David Parkinson, Diane Parks, Matthew D. Perry, Michael A. Metzger and Reed V. Tuckson each ceased to be directors of CTI and members of any committee of CTI’s board of directors.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Matthew D. Perry resigned as Director at CTI BIOPHARMA CORP.
- Action
- resigned
- Role
- Director
Exact text from the filing
As of the Effective Time, Adam R. Craig, Laurent Fischer, David Parkinson, Diane Parks, Matthew D. Perry, Michael A. Metzger and Reed V. Tuckson each ceased to be directors of CTI and members of any committee of CTI’s board of directors.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
CTI BIOPHARMA CORP underwent a change of control involving Swedish Orphan Biovitrum AB (publ) for $9.10 per Share in cash (closed 2023-06-26).
- Action
- change of control
- Counterparty
- Swedish Orphan Biovitrum AB (publ)
- Consideration
- $9.10 per Share in cash
- Closing
- 2023-06-26
Exact text from the filing
tender offer (the “Offer”) on May 25, 2023 to acquire all of the outstanding shares of common stock of CTI, $0.001 par value per share (the “Shares”), at a purchase price of $9.10 per Share in cash (the “Offer Price”), without interest and subject to any applicable withholding taxes. The Offer and related withdrawal rights expired at one minute following
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.